Reevaluation of trkA expression as a biological marker of neuroblastoma by high-sensitivity expression analysis-a study of 106 primary neuroblastomas treated in a single institute
Reevaluation of trkA expression as a biological marker of neuroblastoma by high-sensitivity expression analysis-a study of 106 primary neuroblastomas treated in a single institute
复制标题
DOI：
10.1016/j.jpedsurg.2010.08.021
复制
发表时间：
2010-12-01
影响因子：
2.4
通讯作者：
Yoshida, Hideo
中科院分区：
文献类型：
--
作者：
Hishiki, Tomoro;Saito, Takeshi;Yoshida, Hideo
背景/目的：此前已有研究表明，预后良好的神经母细胞瘤通常表达高水平的神经生长因子受体trkA。我们进行了定量实时聚合酶链反应（PCR）的基础上，在106个NB样本中的trkA的表达分析，并重新评估的trkA.Materials和方法的预后能力：共106个原发性肿瘤从NB患者治疗1988年至2009年进行了分析。MYCN扩增13例。采用TaqMan探针法进行定量PCR。设计引物和探针检测trkA I和trkA II，但不是致癌剪接变体trkA III。结果：通过实时PCR表达分析显示神经母细胞瘤组织内trkA的表达水平范围很广。通过半定量PCR检测不到的极低水平的trkA能够通过该方法定量。trkA主要在肿瘤中表达，结果良好。在排除大规模筛选的神经母细胞瘤的队列中进行trkA表达的进一步分析。引人注目的是，包含年龄，MYCN状态，和trkA表达的多变量分析确定trkA作为唯一的变量，独立预测的44例患者谁presentingclinical.Conclusion预后：高分辨率的表达分析，针对trkA和trkA II可能会增加更多的统计力量trkA作为一种生物标志物。(C)2010年爱思唯尔公司All rights reserved.
Background/Purpose: It has previously been shown that neuroblastomas with favorable prognosis often express a high level of nerve growth factor receptor trkA. We performed an expression analysis of trkA in 106 NB samples based on the quantitative real-time polymerase chain reaction (PCR) and reevaluated the prognostic power of trkA.Materials and methods: A total of 106 primary tumors from NB patients treated from 1988 to 2009 were analyzed. MYCN was amplified in 13 cases. TaqMan probe method was used for quantitative PCR. Primers and probes were designed to detect trkA I and trkA II, but not the oncogenic splice variant trkA III.Results: Expression analysis by real-time PCR revealed a wide range of expression levels of trkA within neuroblastoma tissues. Extremely low levels of trkA that were undetectable by semiquantitative PCR were able to be quantified by this method. trkA was predominantly expressed in tumors with favorable outcome. Further analysis of trkA expression was performed in a cohort excluding mass-screened neuroblastomas. Strikingly, multivariate analysis containing age, MYCN status, and trkA expression identified trkA as the only variable that independently predicts the prognosis of the 44 patients who presented clinically.Conclusion: High-resolution expression analysis targeting trkA and trkA II may add more statistical power on trkA as a biological marker. (C) 2010 Elsevier Inc. All rights reserved.